E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
First-line treatment in patients with locally advanced or metastatic biliary tract cancer, inoperable due to extension of the disease.
|
|
E.1.1.1 | Medical condition in easily understood language |
Locally advanced or metastatic biliary tract cancer |
Patienter med lokalt fremskreden eller spredt kræft i galdeveje |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 25.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008594 |
E.1.2 | Term | Cholangiocarcinoma non-resectable |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008596 |
E.1.2 | Term | Cholangiocarcinoma recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074878 |
E.1.2 | Term | Hilar cholangiocarcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074879 |
E.1.2 | Term | Extrahepatic cholangiocarcinoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10077846 |
E.1.2 | Term | Cholangiocarcinoma metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of gemcitabine/cisplatin plus tocilizumab and gemcitabine/cisplatin, primary: To compare survival rate at 12 months of cisplatin-gemcitabine + tocilizumab versus cisplatin-gemcitabine in patients with locally advanced or metastatic BTC |
|
E.2.2 | Secondary objectives of the trial |
•To compare the progression free survival •To evaluate the overall survival •To evaluate the overall response rate per RECIST1.1 •To evaluate the disease control rate per RECIST1.1 •To assess the safety and toxicity of cisplatin-gemcitabine + tocilizumab versus cisplatin-gemcitabine •To compare for both treatment arms, performance status assessed by both investigator and patient every 3 months until end of treatment • To investigate and compare quality of life during treatment with cisplatin-gemcitabine + tocilizumab versus cisplatin-gemcitabine
Explorartory o investigate whether : • mutations in circulating plasma ctDNA at baseline are associated with disease outcome • circulating serum proteins at baseline and during treatment are associated with disease outcome • serum CRP and IL-6 at baseline and changes during treatment are associated with clinical outcome, improvement of fatigue, development of cancer cachexia or degenerated loss of skeletal muscle (sarcopenia)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Signed informed consent. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care • Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of signing the informed consent form (ICF) • Histological or cytological biliary tract adenocarcinoma. Malignant unspecified tumor cells in cytological specimen are allowed after investigator assessment, mixed histology including adenosquamous carcinoma is allowed • Unresectable locally advanced or metastatic biliary tract carcinoma • ECOG/WHO Performance Status (PS) 0-1 • ≥ 4 weeks since prior major surgery, ≥ 2 weeks since prior minor surgery • Measurable disease using the RECIST1.1 criteria, defined as lesions that can be measured in at least one dimension and which have not been previously irradiated. Longest diameter ≥ 20 mm with conventional techniques or ≥ 10 mm with spiral CT scan or MRI • Fertile women of childbearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [ie, has had menses at any time during the preceding 24 consecutive months]) must use highly effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; or vasectomized partner) while on study IP; and for 3 months following the last dose of chemotherapy; and has negative serum pregnancy test (β -hCG) result at screening • Male subjects: must practice true abstinence (True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following IP discontinuation, even if he has undergone a successful vasectomy. •Acceptable hematology parameters defined as: • Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L • Platelet count ≥ 100 x 10⁹/L •Acceptable liver function with: • Serum bilirubin < 1.5 x upper limit of normal (ULN) • AST and ALT <2.5 x ULN (or 5 x ULN in the presence of liver metastases) •Acceptable renal function with an eGFR ≥ 60 mL/min/1,73m2 •Subjects must have signed and dated a CHOCA approved written informed consent form in accordance with regulatory and institutional guidelines.
|
|
E.4 | Principal exclusion criteria |
• Electrocardiogram (ECG) with significant modifications suggesting a high risk of occurrence of angina pectoris or high risk of arrhythmia • Other malignancies, except adequately treated basal carcinoma or squamous cell carcinoma of the skin or in-situ cervix carcinoma or incidental prostate cancer (T1a, Gleason score ≤ 6, PSA < 0.5 ng/ml), or any other tumor with disease-free survival of ≥ 5 years • History of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by chemotherapy treatment or which could not be controlled; including, but not restricted to: • Active infection requiring antibiotics within 2 weeks before the study inclusion • Concurrent congestive heart failure NYHA (class III - IV) • Unstable angina pectoris, or myocardial infarction within 6 months and/or prior poorly controlled hypertension • Inflammatory bowel disease (colitis, Crohns) or other serious gastrointestinal conditions associated with risk of perforation • Hearing impairment grade ≥ 2 according to CTCAE v 5.0 • Peripheral neuropathy grade ≥ 2 according to CTCAE v 5.0. • Evidence of active tuberculosis (TB), or suspected latent TB based on medical history (e.g. history of untreated TB or TB exposure) without a subsequent negative TB test • Concomitant use of immunosuppressive or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications • No known or suspected allergy to the investigational agents or any agents given in association with this trial • Pregnant or lactating women • Any psychological, familial, sociological, or geographical condition which does not permit protocol compliance and medical follow-up • Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall survival rate at 12 months, the Kaplan-Meier estimate of proportion of patients that survived from the date of randomization by 12 months |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 months after randomisation |
|
E.5.2 | Secondary end point(s) |
• Progression free survival (PFS), defined as the time from the date of randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death due to any cause if sooner • Overall survival (OS), defined as the time from the date of randomization until death due to any cause • Overall response rate (ORR) (ORR = CR + PR). Objective response rate determined by radiographic disease assessments per RECIST 1.1, by investigator assessment • Disease control rate (DCR), (DCR = CR + PR + SD ), according to RECIST 1.1 • Safety (Data on safety parameters) Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments • Performance status every 3 months until end of treatment, assessed by both investigator and patient • Quality of Life (Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0) every 3 months until end of treatment
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Exploratory biomarker analyses |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 10 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 10 |
E.8.9.2 | In all countries concerned by the trial months | 9 |